Introduction
The burden of prosthetic joint infections (PJI) is increasing in developed countries, due to increasing number of patients who underwent arthroplasty [1] . A recent literature review estimated that 0.9% (95% confidence interval, 0.4%-2.2%) of primary total hip arthroplasty will become infected [2] . Despite growing interest in the field, treatment of PJI remains poorly standardized. A significant proportion of patients are initially managed with debridement and prosthesis retention, associated with prolonged antibacterial treatment. This conservative strategy has the theoretical advantage of simplifying the surgical procedure(s), and may allow earlier recovery of functional joint, but success rates are sub-optimal [3] [4] [5] [6] . To better target the patients who are most likely to benefit from this conservative strategy, we aimed to identify factors predictive for success.
Methods
The study was performed in a 1,600-bed tertiary care center, which serves as a referral for the management of complicated osteo-articular infections in the area (population catchment, one million inhabitants). PJI are discussed during weekly multidisciplinary meetings with a panel of specialists in orthopedic surgery, infectious diseases, microbiology, and radiology, in line with national and international guidelines [7, 8] . Antibacterial treatment is initiated per-operatively, after 5 samples of infected tissues have been collected, with a combination of vancomycin/gentamicin/piperacillin-tazobactam when no indication on the pathogen(s) involved is available, or vancomycin/gentamicin for Gram positive cocci, or piperacillin-tazobactam for Gram negative bacilli, or a regimen based on the pathogen(s) susceptibility testing, if available (i.e., when microbiological documentation have been obtained pre-operatively through blood cultures and/or joint aspirates).
We performed an observational study of all patients with PJI initially treated with debridement and prosthesis retention. Cases were identified through a computerized database, and data were extracted from medical charts and surgery reports, through a standardized questionnaire. Data collected included demographics, comorbidities, PJI diagnosis and management, with a special focus on surgical technique, antibacterial treatment, and followup. PJI was defined by presence of pus in the joint, and/or the growth of a virulent microorganism (e.g. Staphylococcus aureus, Gram-negative bacilli) in a specimen of periprosthetic tissue, or synovial fluid. For organism considered as possible contaminant (coagulase-negative staphylococci, Propionibacterium acnes), at least two positive cultures were required [7, 8] . Outcome was classified as failure in case of: i) persistence of PJI signs during treatment, or relapses after treatment discontinuation, with > 1 pathogen isolated from osteo-articular samples, and/or ii) additional surgery required for sepsis control. Request for informed consent was waived by our institutional review board, as the study was retrospective, observational, and collected data anonymously.
Quantitative variables were presented as mean + standard deviation. Qualitative variables were expressed as percentages. Cases classified as failures were compared to cases who did not meet criteria for failure during at least 6 months after antibacterial treatment was discontinued, using Wilcoxon tests for quantitative variables, and Chi 2 tests for qualitative variables. To identify variables independently predictive of failure, we included all variables with P<0.10 in the bivariate analysis, in a multivariate logistic regression analysis step-bystep. Statistical analysis was done with SAS 9.2 (SAS Institute, Cary, NC, USA). P<0.05 was considered statistically significant.
Results

Patients characteristics
Sixty consecutive patients with PJI (34 men, 26 women), were initially managed with prosthesis retention and debridement in our institution during years 2008-2011 (Table I) . Of note, no striking discrepancy with guidelines was identified during medical charts review: all patients could be candidates for debridement, according to published criteria (i.e. PJI with well-fixed prosthesis, without sinus tract, within 30 days of prosthetic implantation, or < 3 weeks from symptoms onset [7, 8] meticillin-resistant), and Enterobacteriaceae. Resistance to rifampin was found in two coagulase-negative staphylococci (25%), and in no S. aureus. Resistance to fluoroquinolones was found in six S. aureus (25%), in four coagulase-negative staphylococci (50%), and in no Enterobacteriaceae. Rifampin was prescribed in 34 patients, and fluoroquinolones in 30 patients.
Outcome
Twenty patients (33%) presented at least one criteria for failure and were managed with additional surgical treatment (n=17), including repeated debridement (n=6), one-stage prosthesis exchange (n=5), two-stage prosthesis exchange (n=8), and/or life-long suppressive antibacterial treatment (n=6). Of note, patients could combine multiple criteria for failure (e.g., need for repeated debridement, then prosthesis exchange or lifelong suppressive antibacterial treatment). Median delay between antibacterial treatment discontinuation and diagnosis of failure was 30 days.
Risk factors for treatment failure
Variables significantly associated with failure on univariate analysis (Table II) 
Discussion
Initial management of PJI with debridement and prosthesis retention is a seducing alternative to prosthesis replacement, and has been associated with increasing rates of success, from 21-28% before 2000 [3] [4] , to 75-78% in more recent series [5] [6] . However, when this conservative strategy is applied to PJI unlikely to be cured without prosthesis removal, their appropriate surgical management is delayed, which may lead to iterative surgeries, prolonged antibacterial treatment, and poor functional outcome [9] [10] [11] [12] [13] [14] . Hence, debridement should be limited to patients likely to benefit from this strategy: PJI with well-fixed prosthesis, without sinus tract, within 30 days of prosthetic implantation, or < 3 weeks from symptoms onset [7, 8] .
In this observational study, although PJI were managed by a multidisciplinary team, with a strict adherence to guidelines, one third of those initially managed with debridement and prosthesis retention were classified as failure, with a median follow-up of 19 months after antibacterial treatment discontinuation. Two variables independently predictive of failure have already been identified by others: S. aureus PJI, and multiple previous surgeries, reduce the probability of success after debridement with prosthesis retention [7, 8] . We aimed to identify modifiable factors associated with improved outcome: first, we found a trend toward better prognosis when debridement was performed through arthrectomy associated with polyethylene replacement ( Table 2 , P=0.08), as recommended [7, 8, 11, 15] . Second, antibacterial regimen duration <3 months post-debridement was independently associated with failure. This suggests that PJI managed with debridement and prosthesis retention should be treated longer than PJI managed with prosthesis replacement, which makes sense, given that the quality of source control is probably lower when prosthesis is retained. Hence, the remaining inoculum would be higher, and would require longer duration of antimicrobial agents.
This study has limitations: i) as it was monocentric, its findings do not necessarily apply to other settings; ii) due to limited sample size, we may have missed factors associated with treatment outcome; iii) the observational design implies that confusion bias may occur, although the prognostic factors we identified remained significant on multivariate analysis; iv) although the median duration of follow-up was 19 months after antibacterial discontinuation (interquartile range, 12-27), late relapses may have been missed. Obviuosly, randomized controlled trials will collect more robust data on optimal antibacterial treatment duration: For example, the French DATIPO trial, that has just been recently completed, should bring 'evidence-based' data in this area, as patients with PJI could be enrolled whether their surgical treatment consisted of prosthesis replacement, or prosthesis retention with debridement.
However, all patients enrolled in the study presented herein were managed by a multidisciplinary team, following international guidelines, and probably reflect current management of PJI in many settings. In conclusion, this study suggests that patients with PJI initially managed with debridement and prosthesis retention are more likely to be cured with no need for additional surgical interventions if PJI occurred in the absence of multiple previous surgeries, when S. aureus is not involved, and if they receive prolonged antibacterial treatment after debridement. 
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